Sonoma Pharmaceuticals, Inc. (SNOA) - Q1 2024 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2024. Sonoma Pharmaceuticals, Inc. is a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for wound care, dermatology, eye care, oral care, animal health, and disinfection. The company operates in 55 countries and is classified as a non-accelerated filer and a smaller reporting company.
Key Financial Metrics
| Metric | Q1 2024 | Q1 2023 |
|---|---|---|
| Revenue | $3.391 million | $3.427 million |
| Gross Profit | $1.306 million | $1.204 million |
| Gross Margin | 39% | 35% |
| Net Loss | $(1.143) million | $(1.418) million |
| Net Loss Per Share (Basic/Diluted) | $(0.07) | $(0.29) |
| Cash and Cash Equivalents | $2.589 million | $3.544 million |
| Working Capital | $8.176 million | $9.546 million |
| Short-Term Debt | $0.204 million | N/A |
| Accumulated Deficit | $(195.492) million | $(190.932) million |
Material Changes vs. Prior Period
- Revenue: Decreased slightly by 1% ($36,000) compared to the prior year. While Europe (+20%) and Latin America (+81%) saw growth, these were offset by declines in the United States (-20%), Asia (-45%), and Rest of World (-49%), primarily attributed to timing of customer orders.
- Profitability: Gross profit increased by 8% ($102,000) due to improved product mix and lower material/transportation costs compared to the prior period. Net loss improved by 19% ($275,000) driven by a reduction in operating expenses and a swing in other income/expense from a loss to a gain due to foreign exchange fluctuations.
- Operating Expenses: Research and Development (R&D) expenses increased 45% ($145,000) due to expanded regulatory efforts. Selling, General, and Administrative (SG&A) expenses decreased 5% ($110,000) due to cost containment efforts.
- Liquidity: Cash and cash equivalents decreased by $539,000 during the quarter. Net cash used in operating activities was $912,000, partially offset by $748,000 in net proceeds from the sale of common stock.
Outlook, Risks, and Contingencies
- Going Concern: Management states there is substantial doubt about the company's ability to continue as a going concern within one year due to a history of losses and an accumulated deficit of $195.5 million. Continued operations depend on securing additional capital through equity offerings, debt, or collaborations.
- Internal Controls: The company disclosed that its disclosure controls and procedures were not effective as of June 30, 2024, due to material weaknesses, specifically a lack of separation of duties in financial reporting. Remediation efforts are underway but not yet fully tested.
- Tax Liability: The company faces a substantial Mexico tax liability, intercompany debt, and accrued interest due in 2027. Management believes current assets are sufficient to cover these obligations.
- Customer Concentration: Revenue is concentrated among a few key customers. In Q1 2024, Customer B accounted for 26% and Customer C for 18% of revenue.
- Foreign Exchange: The company is exposed to currency devaluation risks regarding the Mexican Peso and Euro, which impacted other income/expense significantly.
Investor Verification Checklist
- Verify the status of the material weaknesses in internal controls and the timeline for remediation testing.
- Assess the company's capital raising strategy given the "substantial doubt" regarding going concern status and the reliance on equity markets.
- Review the timing of orders in key regions (US, Asia) to determine if revenue declines are structural or cyclical.
- Monitor the Mexico tax liability and intercompany debt obligations due in 2027.
- Confirm the sustainability of the gross margin improvement (39% vs 35%) amidst potential inflationary pressures on materials and shipping.